Bicycle Therapeutics director granted RSUs, options

Q: What does Bicycle Therapeutics (BCYC) Form 4 report for Janice Bourque?

It reports that director Janice Bourque received a grant of 9,500 RSU-based ordinary shares and a stock option for 19,000 ordinary shares on January 2, 2026.

Q: How many restricted share units did Janice Bourque receive from Bicycle Therapeutics (BCYC)?

She received an RSU award covering 9,500 ordinary shares, vesting in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

Q: What are the terms of the stock option grant to Janice Bourque at Bicycle Therapeutics (BCYC)?

She was granted a stock option for 19,000 ordinary shares at an exercise price of $7.08 per share, vesting in four equal installments on the same 2026 dates and expiring on January 2, 2036.

Q: How many Bicycle Therapeutics (BCYC) ordinary shares does Janice Bourque own after these transactions?

After the reported transactions, she beneficially owns 32,500 ordinary shares directly and holds 19,000 stock options.

Q: Are the Bicycle Therapeutics (BCYC) RSUs granted to Janice Bourque immediately settled in shares?

No. Each RSU represents a contingent right to receive one ordinary share and will deliver shares as the RSUs vest on the specified 2026 dates.

Q: Is Janice Bourque a director or officer of Bicycle Therapeutics (BCYC) according to this Form 4?

She is reported as a director of Bicycle Therapeutics plc and not as an officer or 10% owner in this filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Bicycle Therapeutics plc reported new equity awards to director Janice Bourque. On January 2, 2026, she received 9,500 ordinary shares as a restricted share unit (RSU) award, with the RSUs vesting in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. Each RSU represents a contingent right to receive one ordinary share.

On the same date, she was also granted a stock option to purchase 19,000 ordinary shares at an exercise price of $7.08 per share, vesting in four equal installments on those same 2026 dates and expiring on January 2, 2036. Following these awards, she beneficially owns 32,500 ordinary shares directly and holds 19,000 stock options.

Insider Trade Summary

Net Buyer: 9,500 shares

Net Buy 2 txns

Insider Bourque Janice

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	19,000	$0.00	$0.00
Grant/Award	Ordinary Shares	9,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 19,000 shares (Direct); Ordinary Shares — 32,500 shares (Direct)

Footnotes (3)

F1. Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
F2. Each RSU represents a contingent right to receive one ordinary share.
F3. This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

FAQ

What does Bicycle Therapeutics (BCYC) Form 4 report for Janice Bourque?

It reports that director Janice Bourque received a grant of 9,500 RSU-based ordinary shares and a stock option for 19,000 ordinary shares on January 2, 2026.

What are the terms of the stock option grant to Janice Bourque at Bicycle Therapeutics (BCYC)?

She was granted a stock option for 19,000 ordinary shares at an exercise price of $7.08 per share, vesting in four equal installments on the same 2026 dates and expiring on January 2, 2036.

How many Bicycle Therapeutics (BCYC) ordinary shares does Janice Bourque own after these transactions?

After the reported transactions, she beneficially owns 32,500 ordinary shares directly and holds 19,000 stock options.

Are the Bicycle Therapeutics (BCYC) RSUs granted to Janice Bourque immediately settled in shares?

No. Each RSU represents a contingent right to receive one ordinary share and will deliver shares as the RSUs vest on the specified 2026 dates.

Is Janice Bourque a director or officer of Bicycle Therapeutics (BCYC) according to this Form 4?

She is reported as a director of Bicycle Therapeutics plc and not as an officer or 10% owner in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/06/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bourque Janice

(Last)

(First)

(Middle)

C/O BICYCLE THERAPEUTICS PLC

BLOCKS A & B, PORTWAY BUILDING

(Street)

CAMBRIDGE

CB21 6GS

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BICYCLE THERAPEUTICS PLC [ BCYC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	01/02/2026		A		9,500⁽¹⁾	A	$0⁽²⁾	32,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.08	01/02/2026		A		19,000		⁽³⁾	01/02/2036	Ordinary Shares	19,000	$0	19,000	D

Explanation of Responses:

1. Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

2. Each RSU represents a contingent right to receive one ordinary share.

3. This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

	/s/ Travis Thompson, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR